These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 19127276)

  • 21. Rejuvenation in older adults receiving oral ghrelin.
    Gaugg M
    Ann Intern Med; 2009 May; 150(9):654; author reply 655. PubMed ID: 19414852
    [No Abstract]   [Full Text] [Related]  

  • 22. Growth hormone, IGF-I, and the elderly. Clues to potential therapeutic interventions.
    Rosen CJ
    Endocrine; 1997 Aug; 7(1):39-40. PubMed ID: 9449029
    [No Abstract]   [Full Text] [Related]  

  • 23. Theodore R. Woodward Award. Age-related decline in growth hormone secretion: clinical significance and potential reversibility.
    Thorner MO
    Trans Am Clin Climatol Assoc; 1997; 108():99-105; discussion 105-8. PubMed ID: 9108670
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of growth hormone secretagogues to prevent or treat the effects of aging: not yet ready for prime time.
    Blackman MR
    Ann Intern Med; 2008 Nov; 149(9):677-9. PubMed ID: 18981489
    [No Abstract]   [Full Text] [Related]  

  • 25. Rejuvenation in older adults receiving oral ghrelin.
    Webster J
    Ann Intern Med; 2009 May; 150(9):654-5; author reply 655. PubMed ID: 19414853
    [No Abstract]   [Full Text] [Related]  

  • 26. MK0677, a Ghrelin Mimetic, Improves Neurogenesis but Fails to Prevent Hippocampal Lesions in a Mouse Model of Alzheimer's Disease Pathology.
    Tian J; Wang T; Wang Q; Guo L; Du H
    J Alzheimers Dis; 2019; 72(2):467-478. PubMed ID: 31594237
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Trial watch: Next-generation antimalarial from phenotypic screen shows clinical promise.
    Cully M
    Nat Rev Drug Discov; 2014 Oct; 13(10):717. PubMed ID: 25270950
    [No Abstract]   [Full Text] [Related]  

  • 28. Acylated and unacylated ghrelin administration to blunt muscle wasting.
    Reano S; Graziani A; Filigheddu N
    Curr Opin Clin Nutr Metab Care; 2014 May; 17(3):236-40. PubMed ID: 24572833
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Linking age-related changes in skeletal muscle mass and composition with metabolism and disease.
    Janssen I; Ross R
    J Nutr Health Aging; 2005; 9(6):408-19. PubMed ID: 16395513
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hemiatrophy, juvenile-onset exertional alternating leg paresis, hypotonia, and hemidystonia and adult-onset hemiparkinsonism: the spectrum of hemiparkinsonism-hemiatrophy syndrome.
    Lang AE
    Mov Disord; 1995 Jul; 10(4):489-95. PubMed ID: 7565831
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Peripheral ghrelin treatment stabilizes body weights of senescent male Brown Norway rats at baseline and after surgery.
    Yukawa M; Weigle DS; Davis CD; Marck BT; Wolden-Hanson T
    Am J Physiol Regul Integr Comp Physiol; 2008 May; 294(5):R1453-60. PubMed ID: 18337314
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of hormones in the pathogenesis and management of sarcopenia.
    Kamel HK; Maas D; Duthie EH
    Drugs Aging; 2002; 19(11):865-77. PubMed ID: 12428995
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Modulation of GH/IGF-1 axis: potential strategies to counteract sarcopenia in older adults.
    Giovannini S; Marzetti E; Borst SE; Leeuwenburgh C
    Mech Ageing Dev; 2008 Oct; 129(10):593-601. PubMed ID: 18762207
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sarcopenia and hypertrophy: a role for insulin-like growth factor-1 in aged muscle?
    Hameed M; Harridge SD; Goldspink G
    Exerc Sport Sci Rev; 2002 Jan; 30(1):15-9. PubMed ID: 11806404
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Drugs of Muscle Wasting and Their Therapeutic Targets.
    Sakuma K; Yamaguchi A
    Adv Exp Med Biol; 2018; 1088():463-481. PubMed ID: 30390265
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Endocrine therapies for sarcopenia in older men.
    Solomon A; Bouloux P
    Br J Hosp Med (Lond); 2006 Sep; 67(9):477-81. PubMed ID: 17017617
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Influence of sarcopenia on the development of physical disability: the Cardiovascular Health Study.
    Janssen I
    J Am Geriatr Soc; 2006 Jan; 54(1):56-62. PubMed ID: 16420198
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Age-related muscle mass loss].
    Czarkowska-Paczek B; Milczarczyk S
    Przegl Lek; 2006; 63(8):658-61. PubMed ID: 17441378
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Aging and sarcopenia.
    Thompson DD
    J Musculoskelet Neuronal Interact; 2007; 7(4):344-5. PubMed ID: 18094505
    [No Abstract]   [Full Text] [Related]  

  • 40. The effects of growth hormone and insulin-like growth factor-1 on the aging cardiovascular system and its progenitor cells.
    Devin JK; Young PP
    Curr Opin Investig Drugs; 2008 Sep; 9(9):983-92. PubMed ID: 18729005
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.